1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Colombia Pharmaceuticals and Healthcare Report Q4 2016

Colombia Pharmaceuticals and Healthcare Report Q4 2016

  • October 2016
  • -
  • Business Monitor International
  • -
  • 90 pages

Includes 3 FREE quarterly updates

BMI View:

Colombia's challenging regulatory regime will continue to limit the country's attractiveness to multinational pharmaceutical companies in the coming years. Despite the country's growing rates of medicine consumption, the increasing compulsory license risks and patent regulation burdens as well as substandard pricing controls will remain critical threats to pharmaceutical investment in the country.


Headline Expenditure Projections

- Pharmaceuticals: COP9,101bn (USD3.31bn) in 2015 to COP9,581bn (USD3.19bn) in 2016; +5.3% in local currency and -3.6% in US dollars. Forecast unchanged from previous quarter.

- Healthcare: COP59,373bn (USD21.6bn) in 2015 to COP64,442bn (USD21.5bn) in 2016; +8.5% in local currency and -0.7% in US dollars. Forecast revised slightly downwards due to updated historical data. In our Q416 regional Risk/Reward Index, Colombia is ranked eighth of 19 markets surveyed in the Americas region, unchanged from the previous quarter. The country's overall Risk/Reward score was 51.8, just above the regional average of 50.5. Colombia boasts above-average scores for Rewards and Risks, although we caution that the country's intellectual property regime will continue to represent barriers to multinational involvement. Nevertheless, Colombia will continue to be of interest from a longer-term point of view, not least on account of its substantial population.

Table Of Contents

Colombia Pharmaceuticals and Healthcare Report Q4 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Colombia 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Colombia 2012-2020) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Colombia 2012-2020) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Colombia 2012-2020) 16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Colombia 2012-2020) 17
Prescription Drug Market Forecast 18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Colombia 2012-2020) 19
Patented Drug Market Forecast 20
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Colombia 2012-2020) 22
Generic Drug Market Forecast 23
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Colombia 2012-2020) 25
OTC Medicine Market Forecast 26
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Colombia 2012-2020) 28
Pharmaceutical Trade Forecast 29
Table: Pharmaceutical Trade Data And Forecasts (Colombia 2014-2020) 31
Table: Pharmaceutical Trade Data And Forecasts local currency (Colombia 2014-2020) 31
Pharmaceuticals Risk/Reward Index 32
Americas Risk/Reward Index 32
Colombia Risk/Reward Index 39
Rewards 39
Risks 40
Regulatory Review 41
Intellectual Property Regime 42
Table: Colombia-US FTA Mechanisms Relevant To Intellectual Property 46
Pricing Regime 46
Reimbursement Regime 48
Market Overview 51
Healthcare Sector 52
Table: Healthcare Resources (Colombia 2010-2015) 56
Table: Healthcare Personnel (Colombia 2010-2015) 56
Table: Healthcare Activity (Colombia 2010-2015) 57
Research and Development 57
Table: Pharmaceutical Research and Science Centre (CECIF) Members, 2015 58
Colombia Pharmaceuticals and Healthcare Report Q4 2016$$
Clinical Trials 58
Epidemiology 59
Competitive Landscape 63
Research-Based Industry 63
Table: Members Of Asociación De Laboratorios Farmaceuticos De Investigación (AFIDRO), 2012 64
Table: Multinational Market Activity 66
Table: Leading Pharmaceutical Companies By Revenues, 2011 (COPmn) 67
Pharmaceutical Distribution 68
Table: Leading Pharmaceutical Importers/Wholesalers By Revenues, 2011 68
Pharmaceutical Retail Sector 69
Company Profile 71
Laboratorios Bussie 71
Laboratorios Genfar SA 73
Lafrancol 76
Demographic Forecast 79
Table: Population Headline Indicators (Colombia 1990-2025) 80
Table: Key Population Ratios (Colombia 1990-2025) 80
Table: Urban/Rural Population and Life Expectancy (Colombia 1990-2025) 81
Table: Population By Age Group (Colombia 1990-2025) 81
Table: Population By Age Group % (Colombia 1990-2025) 82
Glossary 84
Methodology 86
Pharmaceutical Expenditure Forecast Model 86
Healthcare Expenditure Forecast Model 86
Notes On Methodology 87
Risk/Reward Index Methodology 88
Index Overview 89
Table: Pharmaceutical Risk/Reward Index Indicators 89
Indicator Weightings 90

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.